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Abstract 
Background: Neurofilament-light (NFL) is a cerebrospinal fluid (CSF) marker of neuroaxonal damage in MS.  
Objective: To determine the correlation of NFL in cerebrospinal fluid (CSF) and serum/plasma, and in plasma 
after switching from injectable MS therapies to fingolimod. 
Methods: A first cohort consisted of MS patients (n=39) and neurological disease controls (n=27) where CSF 
and plasma/serum had been collected for diagnostic purposes. A second cohort (n=243) consisted of patients 
from a post-marketing study of fingolimod. NFL was determined with Single Molecule Array (Simoa™) 
technology (detection threshold 1.95 pg/ml). 
Results: Mean NFL pg/ml (SD) was 341 (267) and 1475 (2358) in CSF and 8.2 (3.58) and 17.0 (16.94) in serum 
from controls and MS, respectively. CSF/serum and plasma/serum levels were highly correlated (n=66, 
rho=0.667, p<10-9 and n=16, rho=0.684, p=0.009, respectively). In patients starting fingolimod (n=243) mean 
NFL pg/ml (SD) in plasma was reduced between baseline (20.4 (10.7)) and at 12 months (13.5 (7.3) p< 3 10-6), 
and levels remained stable at 24 months (13.2 (6.2)). 
Conclusion: NFL in serum and CSF are highly correlated and plasma NFL levels decrease after switching to 




An increasing body of evidence supports the use of markers for inflammatory activity for assessing disease 
activity in MS patients, in turn of relevance for treatment decisions. To date only magnetic resonance imaging 
(MRI) is available in clinical practice, and has shown a high correlation to relapse rates in meta-analyses of 
several large trials 1. Still, it is not established how well clinically available MRI measures (new T1/T2 and 
contrast enhancing lesions) correlate with neuroaxonal damage, in turn a major determinant of permanent 
disability in MS, see e.g. 2. In addition, repeated MRI examinations for monitoring purposes are usually 
restricted to the brain and therefore do not reflect pathology of the spinal cord 3. The number of candidate 
biomarkers of possible value in MS is very large 4. However, in most cases relation to important disease 
processes, such as neuroaxonal damage, or prognostic value for important outcomes, such as long term 
disability, is lacking. Among different markers for neuroaxonal damage, neurofilaments, and especially 
neurofilament light (NFL), has emerged as promising candidates 5, 6 7. Furthermore, several studies have used 
cerebrospinal fluid (CSF) NFL as a marker for therapeutic responses 8 9 10 11 12 13. We have previously shown that 
CSF NFL levels correlate with several biomarkers of intrathecal inflammation, and that both CSF NFL and 
inflammatory markers decrease with age in MS 14. Still, an important obstacle for a wider introduction into 
clinical practice is the requirement of CSF sampling by lumbar puncture. Disanto and co-workers have reported 
serum NFL levels in patients with a clinically isolated syndrome (CIS) using an electrochemiluminescence (ECL)-
based method 15. Serum NFL levels were about three-fold higher in CIS patients compared to healthy controls, 
and within the CIS group NFL correlated with MRI activity and higher disability scores at CIS presentation. 
Though more sensitive than ordinary enzyme-linked immunosorbent assay (ELISA), the ECL-based method has 
a reported analytical sensitivity limit above that normally seen in healthy controls and also with a significant 
overlap with levels seen in MS patients 16. However, we recently developed an ultrasensitive assay for serum 
NF-L using Single Molecule Array (Simoa™) technology (ref: Gisslén M et al., EBioMedicine. 2015 Nov 22;3:135-
40), which represents a novel immune-based ultrasensitive proteins detection method that has a 25-fold 
improved analytical sensitivity as compared to the ECL-based method and shows correlations between serum 
and CSF levels throughout the span of normal to pathological concentrations (ref: Kuhle J et al., Clin Chem Lab 
Med. 2016 Oct 1;54(10):1655-61). The method has further shown correlations of serum NFL levels with MRI 
data in two smaller cohorts of early MS patients 17, 18. We here sought to replicate this finding in a larger cohort 
 of MS patients and controls, and also determined plasma NFL levels in a large real world cohort of MS patients 
switching from injectable therapies to fingolimod.  
 
Methods and material  
Patients and samples 
Two different patient cohorts were used in the study. The first cohort (Cohort 1; n=66 consisted of patients 
attending the Department of Neurology at the Karolinska University Hospital for MS or psychiatric or other 
neurological conditions where sampling of blood and CSF for diagnostic purposes had been undertaken. The 
controls consisted of non-inflammatory neurological disease controls (NINDC) (n=27) patients (56% women, 
mean age 35.2 years, range 20-56) without signs of intrathecal inflammation on standard CSF tests (Table 1). 
The group comprised the following diagnoses; new onset psychotic symptoms n=11, sensory 
symptoms/paresthesia n=10, fatigue n=1, dizziness n=1, headache n=2, visual disturbance n=2. The MS group 
consisted of 39 patients (54% women, mean age 39.6 years, range 23-70), with the following disease courses; 
relapsing-remitting MS (RRMS) in remission n=29, relapsing-remitting MS (RRMS) with clinical relapse 
symptoms with 3 months of sampling n=4, secondary progressive MS (SPMS) n=3, primary progressive MS 
(PPMS) n=3. CSF and plasma/serum were collected at the same time point using standardized protocols. CSF 
was centrifuged immediately and the supernatant was frozen at -80 oC within 1 h.  
The second cohort (Cohort 2) consisted of patients enrolled in a post-marketing study of fingolimod (Gilenya®). 
All clinics in Sweden starting patients on newer MS disease modulatory treatments (DMTs) participate in the 
Immunomodulation and Multiple Sclerosis Epidemiology (IMSE) study. As of March 31st 2016 a total of 1467 
patients had been recruited to the study. All patients are followed over time using the nationwide web-based 
Swedish Neuroregistry (NeuroReg) and donate a plasma sample at baseline and at 12 and 24 months after 
treatment initiation. Samples are sent by surface mail in room temperature to a centralized biobanking unit at 
Karolinska Institutet. From this cohort n=261 individuals were selected based on availability of a baseline 
sample and at least one sample at either 12 or 24 months, as well as information on prior treatment. We 
limited the analysis to patients with RRMS at baseline, who had not made treatment breaks for more than 2 
 weeks, and those which had successful NFL measurements for at least two time points. Thus, n=241 had 
samples from baseline and 12 months, n= 119 from baseline and 24 months, and n=119 from baseline, 12 and 
24 months (Table 2). Twenty-four percent had switched from glatiramer acetate, and 75% from interferons. 
The remaining 2% had either not been treated for MS previously or had been treated with study-drug or pulsed 
corticosteroids.  
All patients provided written consent and the study was approved by the Regional Ethics Committee of 
Stockholm (2009/2107-31/2 and 2011/641-31/4, respectively).  
Determination of NFL using SIMOA 
CSF NFL levels were determined using the NF-Light kit from UmanDiagnostics (UmanDiagnostics, Umeå, 
Sweden) according to the manufacturer’s instructions. Samples were run in duplicate with an intra-assay-
variability of 3.5% and a lower detection threshold of 32 pg/ml. Plasma NFL levels were determined using the 
same NFL antibodies from UmanDiagnostics, transferred onto the Simoa™ platform using a homebrew kit 
(Quanterix Corp, Boston, MA, USA). The lower limit of quantification (LLoQ), determined by the blank mean 
signal + 10 SD, was 1.95 pg/ml. All samples measured were above LLoQ in a pilot run on plasma from 100 
patients and controls, where a range from 2.2 to 403 pg/mL could be demonstrated. The analyses were 
performed by a board-certified laboratory technician using one batch of reagents with intra-assay coefficients 
of variation below 10%.  
Statistical Methods 
Correlation analyses were carried out with two sided Spearman's rank correlation. Differences in NFL levels 
between groups were tested with two sided non-parametric Kruskal-Wallis rank sum or Wilcoxon test. For 
comparison between different lengths of treatment paired Wilcoxon test was used. Statistical tests were 
carried out in Rv 3.3.2.  
 
Results 
Correlation between NFL levels in CSF and serum/plasma 
 We first determined NFL levels in CSF and serum in a heterogeneous group of MS patients and NINDC (Cohort 
1). The mean NFL level in CSF was 341 (SD 267) and 1475 (SD 2358) pg/ml in controls and MS, respectively. In 
the MS cohort, the highest mean NFL levels were found in RRMS patients with a recent relapse (3840 pg/ml), 
whereas mean levels were lower in RRMS patients in remission (1343 pg/ml) and SP/PPMS patients (535 
pg/ml). Subsequently, using the same antibodies transferred onto the Simoa™ platform, NFL levels were 
determined in paired serum samples. At the group level mean NFL levels were 8.2 (SD 3.58) and 17.0 (SD 16.94) 
pg/ml in controls and MS, respectively. The levels of NFL in paired CSF and serum samples were highly 
correlated (rho=0.671, p<10-9, Figure 1A). As a subsequent step we also tested the degree of correlation 
between paired serum and plasma samples in a subpopulation (n=16) of patients from Cohort 1, again 
demonstrating a high degree of correlation (Sr=0.684, p=0.009, Figure 1B).  
 
NFL levels in patients switching to fingolimod 
Next we determined NFL levels in samples collected in context of a large nationwide post-marketing study for 
fingolimod (Cohort 2). The samples were selected based on the availability of a baseline sample and at least 
one follow up sample as well as information on prior treatment with injectable therapies (interferons, 
glatiramer acetate), and was limited to patients with RRMS at treatment start but were otherwise randomly 
chosen. Cohort 2 consisted of 243 individuals and a total of 603 samples (Table 2). 
As a sensitivity analysis, given that samples had been sent by surface mail with a variable time in the post, we 
calculated mean NFL levels in relation to number of days between sampling and arrival, which showed that the 
time (range from 1 to 7 days) the sample had been in the post did not affect the mean level (rho=0.046, 
p=0.60) (Figure 2). Therefore, we did not correct for this in the subsequent analyses. In addition, re-testing to 
exclude batch effects revealed an excellent reproducibility (data not shown). 
At the group level mean plasma NFL measured at baseline, 12 and 24 month after start of fingolimod therapy 
demonstrated a significant 34% reduction at 12 months (13.5 pg/ml, SD 7.34) compared to baseline (20.4 
pg/ml, SD 17.79), where levels remained similar at 24 months (13.20 pg/ml, SD 6.19) compared to 12 months 
(Table 2; Figure 3). The reduction in NFL was associated with a reduced MS Severity Score (MSSS) from a 
 median of 2.30 at start of therapy, 2.00 at 12 months and 1.70 at 24 months. While most subjects (n=191) 
demonstrated lowered levels, a few subjects displayed increased NFL levels after start of fingolimod (n=49).  
Sub-group analyses 
Sex did not affect NFL levels at baseline, but males had a tendency for lower levels than females at both 12 and 
24 months (p=0.09 and p=0.16, respectively). Age was positively correlated with NFL levels at all time points; 
baseline (rho=0.216 p<0.0008), 12 (rho=0.306, p< 2 10-6) and 24 months (rho=0.221 p<0.02). MSSS was 
positively correlated with NFL levels at baseline (rho=0.19, p<0.03), with a tendency for correlation at 12 
months (rho=0.14. p=0.109 but not at 24 months (r=0.10, p=ns).  
Blood lymphocyte counts were not correlated with NFL at baseline (rho=0.023, p=0.80), while there was a weak 
trend, however going in the opposite directions, at 12 (rho=-0.133, p=0.013) and 24 (rho=0.062, p=0.63) 
months. In contrast, the change in lymphocyte numbers displayed a correlation with log change in NFL 
between baseline and 12 months of treatment (rho=0.273 p<0.009). 
 
Discussion  
We here determined NFL levels in paired CSF and serum samples in MS patients and controls, as well as in a 
large cohort of MS patients switching from injectable therapies to fingolimod, where we provide preliminary 
evidence for the usefulness of NFL levels in blood as a biomarker to assess disease activity and therapeutic 
efficacy in MS. Thus, in a large group of MS patients switching from injectable MS therapies to fingolimod a 
highly significant drop in plasma NFL levels had occurred by 12 months and was retained at 24 months. All 
samples were collected in context of a nationwide post-marketing study, which means that measurements 
represent a large real world population with population-based sampling. However, weaknesses include 
incomplete information on some of the clinical variables, especially EDSS and relapses, and lack of MRI data, 
which limit the possibilities of correlation with clinical outcome variables.  
Currently there are no validated fluid biomarkers for disease activity in MS that could function as a 
complement to MRI4. Even if inflammatory activity detectable on MRI is correlated with clinical disease 
measures, standard measures assessing focal active inflammation mainly in the brain white matter through 
 contrast-enhancing or newly appearing T2 lesions only reflect certain aspects of MS disease processes. Thus, 
there is a growing body of evidence from pathological studies that MS comprise also diffuse axonal injuries 
occurring independent of lesions, as well as grey matter pathology 19 20. Volumetric MRI techniques can show 
combined effects of focal and diffuse injuries, but likely will be insensitive for changes over shorter time 
periods, at least at the individual level. Since it is well established that degree of neurodegeneration is the most 
important determinant of long term disability, it would prove useful to identify biomarkers to assess the rate of 
ongoing neurodegeneration. Among such markers the evidence base for CSF NFL is the strongest, including its 
usefulness as a marker for therapeutic response 8 9 10 11 12 13.  
In order to have a more widespread clinical use of neurofilament in MS the assay will have to be developed for 
measuring levels in blood. Until recently this has not been possible, since the sensitivity of most assays have 
been well above of what is seen in healthy controls, which also is the treatment target for patients with MS. 
However, promising preliminary results have been demonstrated with the Simoa™ platform, where the 
analytical sensitivity is well below that of neurofilament levels seen in healthy controls. Interestingly, using this 
analytical technique in a recent study serum NFL levels was shown to accurately detect the onset of 
neurodegeneration in transgenic animal models of neurodegenerative diseases, and in the same study elevated 
blood NFL levels were demonstrated in the human diseases they model 21. Increased serum or plasma NFL 
concentrations further reflect neuroaxonal injury in human neurodegenerative diseases such as atypical 
parkinsonian disorders (Hansson O et al., Neurology. 2017 Feb 8. pii: 10.1212/WNL.0000000000003680; Rojas 
JC et al., Ann Clin Transl Neurol. 2016 Feb 1;3(3):216-25), frontotemporal dementia (Rohrer JD et al., 
Neurology. 2016 Sep 27;87(13):1329-36), Alzheimer’s disease (Mattsson N et al., in press JAMA Neurol) and 
HIV-associated neurocognitive dysfunction (Gisslén M et al., EBioMedicine. 2015 Nov 22;3:135-40), as well as in 
traumatic brain injury (Shahim P et al., Sci Rep. 2016 Nov 7;6:36791). Furthermore, at an Ectrims platform 
presentation interesting data from the Freedoms I study, a phase III study examining the effect of fingolimod 
compared to placebo in RRMS, was communicated by the group of Jens Kuhle. Thus, increased levels of NFL in 
blood were associated not only with the occurrence of gadolinium-enhancing lesions, relapses and increased 
EDSS, but also with brain atrophy 22. Collectively, these findings suggest that blood NFL can be used as a 
biomarker to assess disease activity and therapeutic efficacy in MS. In this context our findings are important as 
they represent a proof-of-principle of the feasibility of testing in a routine clinical context. 
 This also opens interesting perspectives that comprise the possibility to re-analyse archival blood samples from 
clinical trials, sometimes with several years of follow up after the double blinded period, which can be used to 
generate important information on how well this biomarker can predict long term clinical outcomes. Still, some 
caution is warranted with regard to the validity of blood NFL measurements to assess inflammatory disease 
activity at the individual level. Thus, the dynamic range of blood NFL levels is much compressed compared to 
measurements in CSF and might also be affected by individual variability in blood-brain barrier function. For 
example, it is not known if sampling during a low grade inflammation or infection might affect the leakage of 
neurofilament over the blood-brain barrier and thus result in falsely elevated levels in the peripheral 
compartment. Therefore repeated measures over longer periods of time might be needed to more accurately 
assess individual NFL levels. We here also find that NFL levels on fingolimod treatment correlate with age, 
which replicate previous findings from CSF NFL measurements in healthy controls 23, which suggest that 
adjustment for age might be needed. 
In conclusion, we here demonstrate a high degree of correlation between serum and CSF levels of NFL in MS 
patients and controls. Furthermore, we show that in patients switching from injectable MS therapies the 
plasma NFL levels are reduced. Additional studies are needed to demonstrate correlation between blood NFL 
levels and long term clinical outcomes.  
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 Figure legends 
Figure 1. Correlation of neurofilament-light (NFL) levels in cerebrospinal fluid/serum (A) and serum/plasma (B). 
Paired samples of cerebrospinal fluid and serum were obtained during diagnostic procedures from patients 
with MS and non-inflammatory neurological disease controls and show a high degree of correlation between 
the two compartments. In a subset of patients also plasma samples were available, also demonstrating a high 
degree of correlation between plasma and serum. Correlations analyzed with two-sided Spearman's rank 
correlation. 
Figure 2. Neurofilament-light (NFL) levels in plasma obtained from a nationwide post-marketing study of 
fingolimod where samples are sent by surface mail. The time delay between day of sampling and day of arrival 
did not noticeably affect the mean NFL level, suggesting that the assay is robust with regard to handling of 
samples. Correlation analyzed with two-sided Spearman's rank correlation. 
Figure 3. Serum neurofilament-light (NFL) levels in a cohort of patients (n=243) switching from injectable 
therapies to fingolimod, with sampling at baseline and at 12 and 24 months after start of therapy with 
fingolimod. A: At the group level mean plasma NFL demonstrated a significant 34% reduction at 12 months 
compared to baseline, where levels remained similar at 24 months compared to 12 months. B: Plasma NFL 
levels showed a significant correlation with increasing age. Differences between groups analyzed with non-
parametric Kruskal-Wallis rank sum and correlation two-sided Spearman's rank correlation.  
 
